A phase 1/2 study of HKI-272 [neratinib] in combination with trastuzumab (Herceptin) in subjects with advanced breast cancer.

Trial Profile

A phase 1/2 study of HKI-272 [neratinib] in combination with trastuzumab (Herceptin) in subjects with advanced breast cancer.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 May 2015

At a glance

  • Drugs Neratinib (Primary) ; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Puma Biotechnology
  • Most Recent Events

    • 14 May 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2017, as reported by ClinicalTrials.gov.
    • 17 Mar 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 29 Jan 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top